Involving A Micro-organism Or Cell Membrane Bound Antigen Or Cell Membrane Bound Receptor Or Cell Membrane Bound Antibody Or Microbial Lysate Patents (Class 435/7.2)
Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLDN6, including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.
Type:
Grant
Filed:
July 5, 2018
Date of Patent:
February 16, 2021
Assignees:
Ganymed Pharmaceuticals GmbH, Johannes Gutenberg-Universitat Mainz
Inventors:
Ugur Sahin, Ozlem Tureci, Michael Koslowski, Korden Walter, Stefan Woll, Maria Kreuzberg, Bernd Hubner, Michael Erdeljan, Michael Weichel
Abstract: The invention relates to methods and kits for detecting thyroid cancer by detecting differences in the expression of genes that are differentially expressed in thyroid cancer cells.
Type:
Grant
Filed:
February 23, 2017
Date of Patent:
January 12, 2021
Assignee:
Cornell University
Inventors:
Thomas J. Fahey, III, Nimmi Kapoor, Theresa Scognamiglio
Abstract: To provide a cell culture kit including cultured living cells of various donors, and a manufacturing method thereof. The cell culture kit includes a culture plate and living cells cultured thereon. The culture plate includes a plurality of microchambers (33) and living cells derived from various donors are adhered to surfaces of the plurality of microchambers (33). Specifically, living cells D1, D2, and D3 derived from various donors are adhered to the plurality of microchambers (33). In each microchamber (33), living cells derived from one donor or living cells derived from various donors may be cultured. The living cells derived from various donors are adhered and cultured in the cell culture kit as a whole, which makes it possible to provide a cell culture kit to conduct a test using cells derived from various donors.
Type:
Grant
Filed:
January 29, 2016
Date of Patent:
November 17, 2020
Assignees:
Corning Incorporated, Public University Corporation Yokohama City University
Abstract: A method of detecting epithelial cancer is described that includes the steps of: (a) determining the level of beta defensin 3 (BD-3) and beta defensin 2 (BD-2) in a suspect sample obtained from a subject; (b) comparing the level of BD-3 to BD-2 determined in the suspect sample to obtain a suspect BD-3/BD-2 ratio, (c) comparing the suspect BD-3/BD-2 ratio to a healthy BD-3/BD-2 ratio to obtain a diagnostic BD-3/BD-2 ratio; and (d) characterizing the subject as having epithelial cancer if the diagnostic BD-3/BD-2 ratio is greater than 1. A microfluidic device for detecting epithelial cancer using the diagnostic BD-3/BD-2 ratio is also described.
Type:
Grant
Filed:
December 15, 2016
Date of Patent:
October 27, 2020
Assignee:
CASE WESTERN RESERVE UNIVERSITY
Inventors:
Aaron Weinberg, Santosh Ghosh, Umut A. Gurkan
Abstract: The present disclosure is directed dye compounds containing a hydrazinyl substituent and optionally, one or more negatively charged groups, such as sulfonate, phosphate, phosphonate, and/or carboxylate groups and dye compounds containing an aminooxy substitutent. The compounds are useful in the detection of analytes containing aldehyde and ketone groups, including, for example, glycans.
Type:
Grant
Filed:
February 12, 2018
Date of Patent:
October 6, 2020
Assignee:
Life Technologies Corporation
Inventors:
Wenjun Zhou, Kyle Gee, Yolanda Tennico, Peter Slade, Hee Chol Kang, Shaheer Khan, Brian Evans, James Stray
Abstract: Technology for the transition of light and sound over long distances, e.g. TV and radio, has revolutionized society. On the contrary, the technology to perceive a smell remotely is in its infancy, and has severe limitations such as latency, residual and infidelity. A system and methods are disclosed to allow smells to be perceived remotely. It is based on the brain waves associated with the olfactory bulb.
Type:
Grant
Filed:
October 20, 2017
Date of Patent:
September 22, 2020
Inventors:
Lucas Mingzhi Zhou, Lin Zhou, Christopher Li
Abstract: The present invention relates to a method of identifying a compound that binds to or modulates the activity of one or more polypeptides encoding one or more receptors that are involved in the detection and perception of fatty acids.
Type:
Grant
Filed:
August 8, 2019
Date of Patent:
September 8, 2020
Assignee:
MARS, INCORPORATED
Inventors:
Scott Joseph McGrane, Andrew John Taylor, Matthew Ronald Gibbs, Richard Masten Fine, Boris Klebansky
Abstract: This invention relates to the use of analogs of purines that have two tautomeric forms, one formally complementary to thymidine, the other formally complementary to cytidine, and analogs of pyrimidines that have two tautomeric forms, one formally complementary to guanosine, the other formally complementary to adenosine. These uses include the polymerase chain reaction amplification of targets having polymorphisms in primer binding sites and ligation.
Type:
Grant
Filed:
August 27, 2018
Date of Patent:
August 18, 2020
Inventors:
Steven A Benner, Hyo-Joong Kim, Zunyi Yang
Abstract: A system and method automatically predicts an evolution of a cognitive score for a subject by classifying a cognitive data set for the subject into a first or second class by determining the cognitive set of data for each subject of a group, acquiring for each subject a neuropsychological score used for classifying each subject in the first or second class, and training a two-class machine learning classification algorithm on the cognitive data sets of all subjects. For each subject, the cognitive data set is used as input of the algorithm and the obtained classification of the subject as output target of the algorithm. The algorithm classifies each cognitive data set in the first or second class. The evolution of the cognitive score of a subject is predicted by the trained algorithm for automatically classifying a new cognitive dataset for the subject into the first or second class.
Type:
Grant
Filed:
July 2, 2018
Date of Patent:
August 11, 2020
Assignees:
Centre Hospitalier Universitaire Vaudois, Siemens Healthcare GmbH
Inventors:
Jonas Richiardi, Tobias Kober, Julius Popp
Abstract: In one aspect, the invention relates to a method for identifying a compound which modulates the activity of a voltage-gated protein. In certain embodiments, the voltage gate protein is a voltage-gated ion channel. In certain embodiments, the voltage-gated protein is a voltage sensitive phosphatase. In certain embodiments, the voltage-gated protein used in conjunction with the methods of the invention is modified to altered permeability or voltage sensitivity.
Type:
Grant
Filed:
October 17, 2016
Date of Patent:
August 11, 2020
Assignee:
D.E. SHAW RESEARCH, LLC
Inventors:
Morten Østergaard Jensen, David Wayne Borhani, Vishwanath Jogini
Abstract: The present invention provides for compositions and methods for modulating tissue growth using tissue growth modulators, which are agents that either enhance or inhibit tissue growth as desired by a particular indication by modulating the PG or Wnt signaling pathways, or employing modulators of both PG and Wnt signaling pathways for a synergistic effect or highly selective effect.
Type:
Grant
Filed:
June 9, 2016
Date of Patent:
August 11, 2020
Assignees:
CHILDREN'S MEDICAL CENTER CORPORATION, THE GENERAL HOSPITAL CORPORATION
Inventors:
Leonard I. Zon, Trista E. North, Wolfram Goessling
Abstract: Methods are provided herein for identifying whether a cancer patient, for example a colorectal cancer patient, will be responsive to treatment with a therapeutic strategy comprising administration of the FOLFOX regimen (5-fluorouracil, leucovorin, and oxaliplatin). Specified TYMP and UCK2 fragment peptides are precisely detected and quantitated by SRM-mass spectrometry directly in tumor cells, for example colorectal cancer tumor cells, that are collected from tumor tissue obtained from a cancer patient and compared to reference levels in order to determine if the cancer patients will positively respond to treatment with the combination treatment of FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin).
Abstract: The present disclosure relates to a DNA aptamer which specifically binds to an insulin receptor, and a composition for treating diabetes and a composition for diagnosing diabetes which contain the same as an active ingredient, and the aptamer is characterized by being able to treat and diagnose diabetes more effectively than side effects caused by insulin such as increased incidence of cancer and atherosclerosis by having a different binding mechanism from existing insulin.
Type:
Grant
Filed:
May 3, 2016
Date of Patent:
July 28, 2020
Assignees:
Posco, Postech Academy-Industry Foundation
Inventors:
Sung Ho Ryu, Na-Oh Yunn, Jong Hun Im, Ara Koh, Eun Ju Oh, Sehoon Park, Jiyoun Lee, Sung Key Jang, Seungmin Han, Youndong Kim
Abstract: Methods for accurately comparing the levels of ionizable lipids in two cell populations that differ in some respect from each other using mass spectroscopy and isotopic labeling are provided. The methods can be used to identify a change in a lipid of interest in response to a cellular, chemical, genetic, or environmental change to the cell population (i.e., a lipid response to a cell perturbation). The change in the lipid of interest can be a change in composition, rate of synthesis, and/or location of the lipid.
Abstract: Methods for use of structures based on graphene-related materials are disclosed. These structures can be utilized for manipulating the cell transmembrane potential in various biomedical applications.
Abstract: The present invention provides a bioconjugate. The bioconjugate comprises a first molecule comprising an elastin-like peptide (ELP), a second molecule capable of self-associating into an oligomer, and a linker connecting the first molecule with the second molecule. The bioconjugate is self-assembled into particles, which are disassembled when the temperature is increased. Also provided is a method for delivering a bioconjugate to a target matrix, comprising (a) introducing a bioconjugate self-assembled into particles to a target matrix, wherein the bioconjugate comprises a first molecule comprising an elastin-like peptide (ELP), a second molecule capable of self-associating into an oligomer, and a linker connecting the first molecule with the second molecule, and (b) increasing the temperature of the target matrix to disassemble the particles at the target matrix.
Abstract: The present invention is related to methods and compositions effective in regulating glycemic control in subject individuals in need of the regulation of glycemic control. Said individuals may have diabetes or be prediabetic condition receive therapeutically effective amounts of identified secreted proteins in an amount suitable for modulating glycemic control and to thereby treat or prevent diabetes in said subject.
Type:
Grant
Filed:
March 4, 2014
Date of Patent:
April 28, 2020
Assignee:
Joslin Diabetes Center, Inc.
Inventors:
Laurie J. Goodyear, Kristin I. Stanford
Abstract: Antibodies are used as biomarkers to assist in distinguishing gluten immune reactivity and sensitivity, silent celiac disease, Crohn's disease and other gut-related pathologies from classical celiac disease. In one class of embodiments, sera, saliva or other samples from a human or other animal are tested for antibodies to (a) a wheat antigen; (b) a gliadin antigen; and (c) one or more of a wheat germ agglutinin, a gluteomorphin, a glutenin, a deamidated glutenin, a prodynorphin, and a dynorphin. Test results are considered particularly interesting where the wheat antigen and the gliadin antigen are both selected from the group consisting of native and deamidated forms of ?-gliadin 33-mer, ?-gliadin-17-mer, ?-gliadin-15-mer, ?-gliadin-17-mer, and glutenin 21-mer.
Abstract: A biosensor system for the detection of target analytes that includes a living biological cell of a predetermined type; a signal-generating reporter associated with the living biological cell; a signal transduction pathway or other activator mechanism or means associated with the signal-generating reporter; a universal detector element associated with the activator mechanism; and an analyte binding element associated with the universal detector element, wherein the analyte binding element is specific to both the universal detector element and a target analyte.
Type:
Grant
Filed:
December 20, 2017
Date of Patent:
April 7, 2020
Assignee:
Fundamental Solutions Corporation
Inventors:
Thomas J. Zupancic, Joseph D. Kittle, Lingchun Zeng, Srikanth Vedamoorthy, Richard S. Brody, Marvin R. Williams
Abstract: The present invention provides a screening method for a pain suppressor, which method comprises using FLRT3 to select a substance capable of inhibiting FLRT3 expression or a substance capable of inhibiting FLRT3 transport to the spinal cord. In addition, the present invention provides a pharmaceutical composition for prevention or treatment of pain, which pharmaceutical composition comprises, as an active ingredient, a substance capable of inhibiting FLRT3 expression or a substance capable of inhibiting FLRT3 transport to the spinal cord.
Abstract: The invention discloses a method for determining a nucleotide sequence of a nucleic acid segment present in a biological sample, comprising the steps of: a) generating a fluorescent image of the sample by a protocol comprising immunofluorescence detection of at least five different target proteins in the sample; b) selecting a region of interest of the sample by comparing the image to a predetermined criterion; c) removing a subsample from the region of interest, and; d) determining a nucleotide sequence of a nucleic acid segment present in the subsample.
Type:
Grant
Filed:
January 21, 2016
Date of Patent:
March 24, 2020
Assignee:
GE Healthcare Bio-Sciences Corp.
Inventors:
John Richard Nelson, Qingyan Au, Wei Gao, Ryan Charles Heller, Nicholas Hoe, Nam Tran, Nichole Lea Wood
Abstract: The present invention relates to the use of one or more amplicons as temperature calibrators. In some embodiments, the calibrators may be used to calibrate the temperature of a microfluidic channel in which amplification and/or melt analysis is performed. In some embodiments, the amplicons may be genomic, ultra conserved elements and/or synthetic. The amplicon(s) may have a known or expected melt temperature(s). The calibrators may be added to primers of study or may follow or lead the primers of study in the channel. The amplicon(s) may be amplified and melted, and the temperature(s) at which the amplicon(s) melted may be determined. The measured temperature(s) may be compared to the known temperature(s) at which the amplicon(s) was expected to melt. The difference(s) between the measured and expected temperatures may be used to calibrate/adjust one or more temperature control elements used to control and/or detect the temperature of the channel.
Type:
Grant
Filed:
August 31, 2011
Date of Patent:
March 17, 2020
Assignee:
Canon U.S.A., Inc.
Inventors:
Fernando DeCastro, Renee Howell, Sami Kanderian, Johnathan S. Coursey, Kenton C. Hasson, Scott Sundberg
Abstract: The invention relates to a soybean seed extract, method for producing the same and uses of the extract of soybean seeds in promoting wound healing, promoting neuron cell proliferation and/or treating brain diseases and/or neurodegenerative diseases, treating breast cancer, reducing side effects of interfering with DNA and/or RNA replication drugs and/or enhancing pharmaceutical effects of interfering with DNA and/or RNA replication drugs.
Abstract: A protein reporter system comprising at least one reporter including a response element responsive to the binding of a transcription factor, a secreted enzyme backbone and a recognition region for specific binding of an antibody. Multiplexed assays for binding, assaying and quantifying the activity of transcription factors are also described, in which the assays use protein reporters in sets, libraries or other groupings, as necessary to achieve desired quantification.
Abstract: A minimum peak is determined from analysis results, a correction wavelength at which an S/N ratio of the minimum peak is greatest is determined, and the determined correction wavelength is used to execute correction of the minimum peak. A plurality of detector output value correction method are registered in a processor, correction method is selected from default correction method or from among a plurality of preset correction methods according to an object to perform correction.
Abstract: In various implementations, a noninvasive, food sensitivity test may be utilized to identify one or more food sensitivities. A fecal sample may be obtained. The food sensitivity test may be performed on the obtained fecal sample. One or more food sensitivities may be identified based on the food sensitivity test.
Abstract: An antibody or a fragment thereof directed against an epitope including or being constituted by at least six contiguous amino acids in the SEQ ID NO: 1 or a conformational epitope comprising or being constituted by at least six amino acids of SEQ ID NO: 1 which are always in the order of the sequence, and its use for the prognosis and/or the diagnosis of a cancer.
Type:
Grant
Filed:
January 14, 2016
Date of Patent:
January 7, 2020
Assignees:
UNIVERSITE GRENOBLE ALPES, UNIVERSITE DE LAUSANNE
Abstract: The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
Type:
Grant
Filed:
March 12, 2014
Date of Patent:
December 10, 2019
Assignee:
PROTHENA BIOSCIENCES LIMITED
Inventors:
Peter Seubert, Philip James Dolan, III, Yue Liu, Robin Barbour
Abstract: A method includes receiving multiple compound muscle action potential values (CMAPs), wherein each CMAP is an onset latency, a peak latency, a conduction velocity, or a response amplitude measured from a baseline; for each of the CMAPs and for each of a number parameters calculated from the CMAPs, determining a corresponding demyelinating boundary value using a normal value from a preselected population; determining whether each of the CMAPs and each of the parameters exceeds the corresponding demyelinating boundary value; determining one or more demyelinated nerve pathways based on which of the CMAPs and the parameters exceeds the corresponding demyelinating boundary value; indicating on a display which of the CMAPs and the parameters exceed the corresponding demyelinating boundary value; and displaying, in pictorial form, an anatomical diagram indicating the demyelinated nerve pathways.
Type:
Grant
Filed:
November 4, 2014
Date of Patent:
December 3, 2019
Assignee:
The Research Foundation of State University of New York
Inventors:
Paul Jacob Maccabee, Lawrence Philip Eberle
Abstract: The method provides a hyaluronic-acid binding based technique to separate functionally competent and mature sperm. The method for extracting viable sperms from a semen sample comprises incubating functionalized HA with functionalized paramagnetic beads to obtain a plurality of HA coated paramagnetic beads. The method further comprises incubating the plurality of HA coated paramagnetic beads with the semen sample to obtain a first population and a second population of sperm. The first population comprises sperm bound to the plurality of HA coated paramagnetic beads and the second population comprises sperms not bound to the plurality of HA coated paramagnetic beads. The method comprises magnetically separating the first population from the second population and separating sperms from the plurality of HA coated paramagnetic beads in the separated first population to obtain the viable sperms.
Abstract: A group of indolealkylamino-withasteroid conjugates, isolated and purified from Withania somnifera, are described. A synthetic method of making an indolealkylamino-withasteroid compound is provided. In vitro acetyl cholinesterase inhibitory activity and methods for treatment of dementia and dementia-related disorders, such as Alzheimer's disease, and anxiety and depressive disorders in mammals are demonstrated with these novel compositions.
Type:
Grant
Filed:
July 21, 2015
Date of Patent:
October 22, 2019
Assignee:
Natreon, Inc.
Inventors:
Shibnath Ghosal, Muruganandam Veeraragavan, Sanyasi R. Kalidindi
Abstract: In certain aspects, the present invention provides methods for determining whether a Her-2 positive cancer is likely to respond to treatment with a Her2-acting agent and/or whether a patient with a Her-2 positive cancer is likely to have a slow disease progression. In other aspects, the present invention is drawn to methods for determining whether a subject with a Her-2 positive cancer is unlikely to respond to treatment with at least one chemotherapeutic agent in addition to a Her2-acting agent and/or whether a patient with a Her-2 positive cancer is likely to have a fast disease progression.
Type:
Grant
Filed:
December 19, 2008
Date of Patent:
September 17, 2019
Assignee:
Monogram Biosciences, Inc.
Inventors:
Weidong Huang, Jeff Sperinde, Michael Bates, Colombe Chappey, John William Winslow
Abstract: The invention provides a multiparametric method of assessing the reaction of a patient's immune system to a test subject. The invention compares a patient sample reacted with a test sample and a third party sample and combines the assessments of the multiple parameters to correlate the test reaction with a clinical event.
Type:
Grant
Filed:
August 16, 2017
Date of Patent:
August 6, 2019
Assignee:
University of Pittsburgh—Of the Commonwealth System of Higher Education
Abstract: The present invention provides methods for the determination of the activation level of Receptor Tyrosine kinases, e.g. phosporylated HER3, for the selection of patients for disease treatment. Methods are also provided for the evaluation of the biological and pharmacodynamic effects of an active substance and/or its efficacy in disease treatment, utilizing a tissue sample from a test subject, for example tumor material or normal tissue such as skin or hair follicle. Further, methods for the treatment of HER receptor-associated diseases are disclosed.
Abstract: Methods for producing a population of human-derived glial restricted progenitor cells (GRPs) with decreased potentially unintended or undesired cellular phenotypes and/or decreased standard deviation in the cells of the population are provided. Also provided are antibody panels and gene expression profiles to characterize GRPs and a method for its use in characterizing GRP cells. In addition methods for use of these GRP cells to generate astrocytes and/or oligodendrocytes, to re-myelinate neurons and to treat glial cell related and other neurodegenerative diseases or disorders or injuries or damage to the nervous system are provided. A method to manufacture neural cells depleted of A2B5 positive cells is also provided.
Type:
Grant
Filed:
November 9, 2010
Date of Patent:
July 16, 2019
Assignee:
Q THERAPEUTICS, INC.
Inventors:
Robert Sandrock, James T. Campanelli, Deborah A. Eppstein
Abstract: The present invention discloses cryopreserved recombinant cells for screening drug candidates that transiently overexpress one or more drug transporter proteins and/or drug metabolizing enzymes. Advantageously, such cells provide a cost-efficient consumable product that streamlines the process of screening whether drug candidates are substrates or inhibitors of drug transporter proteins and/or drug metabolizing enzymes.
Abstract: Newly identified mammalian taste-cell-specific G Protein-Coupled Receptors and the genes encoding said receptors are described. Specifically, T2R taste G Protein-Coupled Receptors that are believed to be involved in bitter taste sensation, and the genes encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors. Methods for representing taste perception of a particular tastant in a mammal are also described, as are methods for generating a novel molecules or combinations of molecules that elicit a predetermined taste perception in a mammal, and methods for simulating one or more tastes.
Abstract: The present invention aims to provide a pharmaceutical composition for cancer treatment, which comprises a novel monoclonal antibody binding to SLC6A6 or its extracellular region and a chemotherapeutic agent conjugated therewith, as well as a therapeutic method in which the monoclonal antibody or a therapeutic agent composed of the monoclonal antibody conjugated with a chemotherapeutic agent is used in combination with a chemotherapeutic agent. The present invention provides a pharmaceutical composition comprising an antibody conjugate configured such that a monoclonal antibody having higher affinity than conventional antibodies and recognizing native SLC6A6 or a native polypeptide of an extracellular region of SLC6A6 is conjugated with an anticancer agent or the like having activity against cancer and other hyperproliferative diseases.
Abstract: The invention relates to mammalian cells comprising at least one prokaryotic two-component signaling (TCS) pathway comprised of an activator protein A, a response regulator (RR) protein B activated by said protein A, such activation leading to an activated RR protein B, and an output gene C operably linked to a promoter. Transcription from said promoter is activated by activated RR protein B, and the expression of output gene C defines at least a first state (0, no transcription) and a second state (1, detectable transcription). The invention further relates to logic gates designed from such cells, and methods for integrating a plurality of output signals based on the cells and logic gates of the invention.
Type:
Grant
Filed:
June 4, 2015
Date of Patent:
December 25, 2018
Assignee:
ETH ZURICH
Inventors:
Yaakov Benenson, Jonathan Hansen, Krishna Kumar Swaminathan
Abstract: A cell information obtaining method comprises causing a plurality of fluorescent substances having different fluorescence wavelengths from each other to be bound to a test substance contained in a cell, applying light to the cell to cause fluorescences having different wavelengths and intensities to be generated from the plurality of fluorescent substances, and obtaining a first fluorescence information and a second fluorescence information on the basis of the generated fluorescences.
Abstract: Structures based on graphene-related materials, methods for their preparation, and methods for their use are disclosed. These structures can be utilized for manipulating the cell transmembrane potential in various biomedical applications.
Abstract: The present invention relates to the use of a control marker for implementing analysis methods on spots, in particular in the context of multiplex analyses. The present invention thus relates to solid supports containing said control marker, their preparation method and their use in analysis methods. The present invention makes it possible to verify the presence, location and/or integrity of the spots at the end of the analysis method, and thus to secure the obtained results while guaranteeing that the yielded result indeed results from a present, intact and localized spot.
Type:
Grant
Filed:
April 8, 2015
Date of Patent:
November 27, 2018
Assignee:
BIO-RAD EUROPE GMBH
Inventors:
Agnes Roseline Claude Pouzet, Vincent Doury, Laurent Emmanuel Fournier, Christophe Rene Roger Vedrine
Abstract: This disclosure concerns the discovery of the use of fenoterol analogs for regulating cannabinoid (CB) receptor activity-related disorders and disease, such as dysregulated CB receptors, including treating a disorder or disease, such as a glioblastoma, hepatocellular carcinoma, liver cancer, colon cancer, and/or lung cancer, which is associated with altered cannabinoid receptor activity. In one example, the method includes administering to a subject having or at risk of developing a disorder or disease regulated by CB receptor activity an effective amount of a fenoterol analog to reduce one or more symptoms associated with the disorder or disease regulated by CB receptor activity.
Type:
Grant
Filed:
August 1, 2016
Date of Patent:
November 20, 2018
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Irving William Wainer, Michel Bernier, Rajib Kumar Paul
Abstract: The present invention relates to fusion proteins for the expression of G-protein coupled receptor proteins (GPCR) with the fusion partners, as inserted fragments, from mammalian cells. The fusion partners are from a fragment of APJ protein (“the APJ protein fragment”) or a fragment with homology of more than 90% similarity to the APJ protein fragment; or a fragment of RGS16 protein (the “RGS16 protein fragment”) or a fragment with homology of more than 90% similarity to the RGS16 protein fragment; or the fragment of DNJ protein (the “DNJ protein fragment”) or a fragment with homology of more than 90% similarity to DNJ protein fragment. The fusion expression of GPCR with the above mentioned fusion partners can improve the protein yield and stability when purified from cells. Therefore, these fusion protein partners can be widely used for the study of GPCR proteins.
Type:
Grant
Filed:
April 24, 2017
Date of Patent:
October 23, 2018
Assignee:
VIVA BIOTECH (SHANGHAI) LTD.
Inventors:
Jianhua Cai, Jian Shen, Fan Jiang, Na Li, Wentao Wei, Xiuhong Zeng, Xiaoyan Su, Min Han, Delin Ren, Chen Mao
Abstract: Monoclonal antibodies and fragments thereof are capable of binding to a serum form of human TK1. Kits and methods involve the use of such monoclonal antibodies or fragments.
Abstract: Novel nucleoside phosphoramidite building blocks for preparation of synthetic oligonucleotides containing at least one phosphotriester linkage conjugated to a monosaccharide and synthetic processes for making the same are disclosed. Furthermore, oligomeric compounds are prepared using said building blocks, preferably followed by removal of protecting groups to provide monosaccharide-conjugated oligonucleotides.
Type:
Grant
Filed:
December 4, 2015
Date of Patent:
October 2, 2018
Assignee:
AM CHEMICALS LLC
Inventors:
Andrei Pavel Guzaev, Vladimir Y. Vvedenskiy
Abstract: This invention relates to electrophysiological assays that measure sodium conductance activity of a delta human epithelial sodium channel (ENaC) in the presence and absence of delta hENaC enhancers. Also, the invention generally relates to assays for identifying compounds that enhance the activity of delta hENaC, especially in an oocyte expression system. These compounds have potential application in modulating (enhancing) salty taste perception.
Type:
Grant
Filed:
January 26, 2007
Date of Patent:
September 18, 2018
Assignee:
SENOMYX, INC.
Inventors:
Bryan Moyer, Min Lu, Fernando Echeverri, Hong Chang
Abstract: The invention relates to carbohydrate ligands presenting the minimal Human Natural Killer-1 (HNK-1) epitope that bind to anti-MAG (myelin-associated glycoprotein) IgM antibodies, and their use in diagnosis as well as for the treatment of anti-MAG neuropathy. In particular, the invention relates to disaccharides of formula (I) and (II) wherein Z is optionally substituted phenyl, heteroaryl, arylcarbonyl, or heteroarylmethyl, and to therapeutically acceptable polymers comprising a multitude of substituents of formula (I) and/or formula (II), wherein Z is a bifunctional linker connecting the disaccharides to the polymer backbone.
Type:
Grant
Filed:
March 12, 2015
Date of Patent:
June 12, 2018
Assignee:
UNIVERSITAET BASEL
Inventors:
Beat Ernst, Ruben Herrendorff, Andreas Steck, Fan Yang
Abstract: This invention relates, e.g., to a method for enhancing exon skipping in a pre-mRNA of interest, comprising contacting the pre-mRNA with an effective amount of a compound such as, for example, Perphenazine, Flupentixol DiHCl, Zuclopenthixol or Corynanthine HCl, or a compound which shares a similar 2-D structure and activity level with one of these compounds, or a pharmaceutically acceptable salt, hydrate, solvate, or isomer of the compound, and, optionally, with an antisense oligonucleotide that is specific for a splicing sequence in the pre-mRNA Methods for treating Duchenne muscular dystrophy (DMD) are disclosed.
Type:
Grant
Filed:
September 30, 2014
Date of Patent:
May 29, 2018
Assignee:
The Regents of The University of California
Inventors:
Genevieve C. Kendall, Stanley F. Nelson, M. Carrie Miceli